FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Disclosed are a bispecific antibody and a fusion protein for specific binding to GD2 and CD3. Also disclosed are pharmaceutical compositions, nucleic acid, an expression vector, a host cell and a method of producing a bispecific antibody. Also described is a method of destroying neuroblastoma cells, a method of inhibiting growth of neuroblastoma and a method for increasing half-life of a bispecific antibody.
EFFECT: present invention can find further application in increasing the activity of antibodies mobilizing T-cells for immunotherapy of malignant entities, particularly neuroblastoma.
18 cl, 11 dwg, 19 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
